Sucampo/Takeda’s Amitiza First To Fill Zelnorm Void In IBS Market
Executive Summary
With the addition of an irritable bowel syndrome indication, Sucampo Pharmaceuticals has expanded the market opportunity for its chronic idiopathic constipation drug Amitiza by about 20 million patients
You may also be interested in...
Government-funded Hong Kong Startup Looks To Run Traditional Chinese Medicine Treatment For IBS Through Clinical Trials
HONG KONG - Developing a treatment for irritable bowel syndrome has proven to be an elusive goal and there is no product available in Asia to fully treat the disease, but a government-funded Hong Kong startup hopes a traditional Chinese medicine can stand the rigors of pharmaceutical approvals and fill an unmet medical need
Cymbalta Fibromyalgia Approval Sets Another REMS Precedent
FDA's approval of Lilly's Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation and Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides
Cymbalta Fibromyalgia Approval Sets Another REMS Precedent
FDA's approval of Lilly's Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation and Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides